Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
Pharmaceutics · 28.03.2023 · 15 (4) · 1083
DOI: 10.3390/pharmaceutics15041083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 28.03.2023. Verfasst von Rania Moataz El-Dahmy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Central Axis, Cairo 12585, Egypt. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Olmesartan medoxomil (OLM) is a first-line antihypertensive drug with low oral bioavailability (28.6%). This study aimed to develop oleogel formulations to decrease OLM side effects and boost its therapeutic efficacy and bioavailability. OLM oleogel formulations were composed of Tween 20, Aerosil 200, and lavender oil. A central composite response surface design chose the optimized formulation, containing Oil/Surfactant (SAA) ratio of 1:1 and Aerosil % of 10.55%, after showing the lowest firmness and compressibility, and the highest viscosity, adhesiveness, and bioadhesive properties (Fmax and Wad). The optimized oleogel increased OLM release by 4.21 and 4.97 folds than the drug suspension and gel, respectively. The optimized oleogel formulation increased OLM permeation by 5.62 and 7.23 folds than the drug suspension and gel, respectively. The pharmacodynamic study revealed the superiority of the optimized formulation in maintaining normal blood pressure and heart rate for 24 h. The biochemical analysis revealed that the optimized oleogel achieved the best serum electrolyte balance profile, preventing OLM-induced tachycardia. The pharmacokinetic study showed that the optimized oleogel increased OLM’s bioavailability by more than 4.5- and 2.5-folds compared to the standard gel and the oral market tablet, respectively. These results confirmed the success of oleogel formulations in the transdermal delivery of OLM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Central Axis, Cairo 12585, Egypt.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
- Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 04184, United Arab Emirates.
- Medical Biochemistry Department, Medicine and Clinical Studies Research Institute, National Research Centre, Giza 12622, Egypt.
- Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Al Abdeyah, Makkah 24381, Saudi Arabia.
- Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Assuit 71524, Egypt.
ORCID-Profile: Rania Moataz El-Dahmy, Ibrahim Elsayed, Riyad A Almaimani, Mahmoud Zaki El-Readi, Bassant M M Ibrahim
Zitieren
APA
El-Dahmy, R. M., Elsayed, I., Hussein, J., Althubiti, M., Almaimani, R. A., El-Readi, M. Z., Elbaset, M. A., & Ibrahim, B. M. M. (2023). Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation. Pharmaceutics, 15(4), 1083. https://doi.org/10.3390/pharmaceutics15041083
Vancouver
El-Dahmy RM, Elsayed I, Hussein J, Althubiti M, Almaimani RA, El-Readi MZ, et al. Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation. Pharmaceutics. 2023;15(4):1083. doi:10.3390/pharmaceutics15041083
BibTeX
@article{ElDahmy2023,
author = {El-Dahmy, Rania Moataz and Elsayed, Ibrahim and Hussein, Jihan and Althubiti, Mohammad and Almaimani, Riyad A and El-Readi, Mahmoud Zaki and Elbaset, Marawan A and Ibrahim, Bassant M M},
title = {Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {4},
pages = {1083},
doi = {10.3390/pharmaceutics15041083}
}
EUVIMED